**New Drug Approval**

*Sofosbuvir, velpatasvir and voxilaprevir*

Date of Approval: July 18, 2017  
*Treatment for: Chronic Hepatitis C*

Vosevi (sofosbuvir, velpatasvir and voxilaprevir or SOF/VEL/VOX) is a fixed-dose combination of a nucleotide analogue NS5B polymerase inhibitor (SOF), a pangenotypic NS5A inhibitor (VEL), and a pangenotypic NS3/4A protease inhibitor (VOX) for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.

*Neratinib*

Date of Approval: July 17, 2017  
*Treatment for: Breast Cancer -- Adjuvant*

Company: Puma Biotechnology, Inc.

The U.S. Food and Drug Administration (FDA) has approved Nerlynx (neratinib), a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy.

**Guselkumab**

Date of Approval: July 13, 2017  
*Treatment for: Plaque Psoriasis*

The U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab), an interleukin-23 blocker for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

**L-glutamine**

Date of Approval: July 7, 2017  
*Treatment for: Sickle Cell Anemia*

Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia.

**Triptorelin**

Date of Approval: June 29, 2017  
*Treatment for: Precocious Puberty*

Triptodur (triptorelin) is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients with central precocious puberty.

**Betrixaban**

Date of Approval: June 23, 2017  
*Treatment for: Prevention of Venous Thromboembolism*

Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness.

**C1 esterase inhibitor (human) Subcutaneous Injection**

Date of Approval: June 22, 2017  
*Treatment for: Hereditary Angioedema*

Haegarda (C1 esterase inhibitor (human)) is a low-volume subcutaneous (SC) C1-esterase inhibitor (C1-INH) replacement therapy to prevent Hereditary Angioedema (HAE) attacks.

**Rituximab and hyaluronidase**

Date of Approval: June 22, 2017  
*Treatment for: Follicular Lymphoma; Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia*

Rituxan Hycela (rituximab and hyaluronidase human) is a subcutaneous monoclonal antibody and hyaluronidase human formulation for the treatment of adult patients with follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

**Delafloxacin**

Date of Approval: June 19, 2017  
*Treatment for: Skin and Structure Infection*

Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

*Source: drugs.com*

Information collected and compiled by:  
Mr. Md. Akbar Hossain  
Assistant Professor  
Department of Pharmacy  
ASA University, Dhaka